entertainment -WSS

entertainment

author：fashion 2025-09-30 18:17:44 - browse：557

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Florida health officials providing scant details on measles cases

WSS

Doctors find melanoma drugs effective against rare brain cancer

Medicare drug price negotiation continues, as pharma counteroffers

Ancient Greek ideas underpin modern concepts of pregnancy

He's 19 months old and has one of the world’s rarest diseases

How Medicaid coverage policies for immigrants impact new moms

Longer MASH drug regimen improved liver, Akero study finds

entertainment

entertainment

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Streamlined flu vaccines recommended by FDA advisory panel

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lack of health data on LGBTQ+ people has serious consequences

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: BridgeBio, Akero, and human embryo models

In Memoriam: Notable people who died in 2023

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Group opposing PBM reform sets lobbying record

hotspot

Medicare drug price negotiation continues, as pharma counteroffers

Ozempic has benefits for kidney disease as well as diabetes

Families look for replacement for GSK asthma drug Flovent

Pregnant women don't need prenatal multivitamins, study concludes

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Sanders adds drug shortage policies to pandemic preparedness bill

explore

hotspot

knowledge

entertainment